E. Ohman J:Or Asset Management Ab Abb Vie Inc. Transaction History

E. Ohman J:Or Asset Management Ab

$4.04 Trillion
Q3 2024

37 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 05, 2024	SELL	$144.61 - $166.54 $32.8 Million - $37.8 Million	-226,889 Closed	0 $0
Q4 2022 Apr 05, 2024	SELL	$138.31 - $165.87 $3.87 Million - $4.65 Million	-28,010 Reduced 10.99%	226,889 $36.7 Billion
Q3 2022 Apr 05, 2024	SELL	$134.21 - $153.93 $1.3 Million - $1.49 Million	-9,678 Reduced 3.66%	254,899 $34.2 Billion
Q2 2022 Apr 05, 2024	SELL	$137.62 - $174.96 $1.32 Million - $1.68 Million	-9,590 Reduced 3.5%	264,577 $40.5 Billion
Q1 2022 Apr 05, 2024	BUY	$131.98 - $163.75 $31.9 Million - $39.6 Million	242,060 Added 753.92%	274,167 $44.4 Billion
Q4 2021 Apr 05, 2024	SELL	$107.43 - $135.93 $5.04 Million - $6.38 Million	-46,900 Reduced 59.36%	32,107 $4.35 Billion
Q3 2021 Apr 05, 2024	BUY	$106.4 - $120.78 $266,000 - $301,950	2,500 Added 3.27%	79,007 $8.52 Billion
Q2 2021 Apr 05, 2024	BUY	$105.21 - $117.21 $599,697 - $668,097	5,700 Added 8.05%	76,507 $8.62 Billion
Q1 2021 Apr 05, 2024	BUY	$102.3 - $112.62 $3.56 Million - $3.92 Million	34,800 Added 96.65%	70,807 $7.66 Billion
Q4 2020 Apr 05, 2024	SELL	$80.49 - $108.67 $217,323 - $293,409	-2,700 Reduced 6.98%	36,007 $3.86 Billion
Q3 2020 Apr 05, 2024	SELL	$85.91 - $100.83 $197,593 - $231,909	-2,300 Reduced 5.61%	38,707 $3.39 Billion
Q2 2020 Apr 05, 2024	BUY	$73.37 - $98.18 $477,418 - $638,857	6,507 Added 18.86%	41,007 $4.03 Billion
Q1 2020 Apr 05, 2024	SELL	$64.5 - $97.79 $180,600 - $273,812	-2,800 Reduced 7.51%	34,500 $2.63 Billion
Q4 2019 Apr 05, 2024	SELL	$72.13 - $90.25 $2.08 Million - $2.6 Million	-28,800 Reduced 43.57%	37,300 $3.3 Billion
Q3 2019 Apr 05, 2024	BUY	$62.98 - $75.72 $195,238 - $234,732	3,100 Added 4.92%	66,100 $5.01 Billion
Q2 2019 Apr 05, 2024	BUY	$65.7 - $83.98 $197,100 - $251,940	3,000 Added 5.0%	63,000 $4.58 Billion
Q1 2019 Apr 05, 2024	SELL	$77.14 - $90.79 $323,988 - $381,318	-4,200 Reduced 6.54%	60,000 $4.84 Billion
Q4 2018 Apr 05, 2024	SELL	$77.85 - $96.01 $669,510 - $825,686	-8,600 Reduced 11.81%	64,200 $5.92 Billion
Q3 2018 Apr 05, 2024	BUY	$88.91 - $98.84 $640,152 - $711,648	7,200 Added 10.98%	72,800 $6.89 Billion
Q2 2018 Apr 05, 2024	BUY	$89.78 - $106.23 $1.82 Million - $2.16 Million	20,300 Added 44.81%	65,600 $6.08 Billion
Q1 2018 Apr 05, 2024	SELL	$92.01 - $123.21 $202,422 - $271,062	-2,200 Reduced 4.63%	45,300 $4.29 Billion
Q4 2017 Apr 05, 2024	BUY	$89.56 - $98.21 $438,844 - $481,228	4,900 Added 11.5%	47,500 $4.59 Billion
Q3 2017 Apr 05, 2024	BUY	$69.85 - $89.22 $139,700 - $178,440	2,000 Added 4.93%	42,600 $3.79 Billion
Q2 2017 Apr 05, 2024	SELL	N/A	-2,300 Reduced 5.36%	40,600 $2.94 Billion
Q1 2017 Apr 05, 2024	BUY	N/A	4,500 Added 11.72%	42,900 $2.8 Billion
Q4 2016 Apr 05, 2024	BUY	N/A	3,500 Added 10.03%	38,400 $2.4 Billion
Q3 2016 Apr 05, 2024	BUY	N/A	1,800 Added 5.44%	34,900 $2.2 Billion
Q2 2016 Apr 05, 2024	BUY	N/A	3,100 Added 10.33%	33,100 $2.05 Billion
Q1 2016 Apr 05, 2024	SELL	N/A	-3,000 Reduced 9.09%	30,000 $1.71 Billion
Q3 2015 Apr 05, 2024	SELL	N/A	-3,000 Reduced 8.33%	33,000 $1.8 Billion
Q2 2015 Apr 05, 2024	BUY	N/A	2,700 Added 8.11%	36,000 $2.42 Billion
Q4 2014 Apr 05, 2024	SELL	N/A	-2,400 Reduced 6.72%	33,300 $2.21 Billion
Q2 2014 Apr 05, 2024	SELL	N/A	-2,700 Reduced 7.03%	35,700 $2.01 Billion
Q4 2013 Apr 05, 2024	SELL	N/A	-2,100 Reduced 5.19%	38,400 $2.04 Billion
Q3 2013 Apr 05, 2024	BUY	N/A	3,000 Added 8.0%	40,500 $1.81 Billion
Q2 2013 Apr 05, 2024	SELL	N/A	-5,700 Reduced 13.19%	37,500 $1.55 Billion
Q1 2013 Apr 05, 2024	BUY	N/A	43,200	43,200 $1.76 Billion

Others Institutions Holding ABBV

# of Institutions

3,846

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $295B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.

Account